{
    "Trade/Device Name(s)": [
        "PATHFAST\u00ae hs-cTnI-II",
        "PATHFAST\u00aehs-cTnI-II"
    ],
    "Submitter Information": "PHC Corporation",
    "510(k) Number": "K231974",
    "Predicate Device Reference 510(k) Number(s)": [
        "K100130"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MMI"
    ],
    "Summary Letter Date": "March 1, 2024",
    "Summary Letter Received Date": "March 4, 2024",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "cardiac Troponin I (cTnI)"
    ],
    "Specimen Type(s)": [
        "Whole blood",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "PATHFAST\u00ae instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Kit",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for PATHFAST\u00ae hs-cTnI-II high sensitivity cardiac troponin I assay for quantitative measurement in whole blood and plasma",
    "Indications for Use Summary": "In vitro diagnostic test for quantitative measurement of cardiac Troponin I (cTnI) in heparinized or EDTA whole blood and plasma as an aid in the diagnosis of acute myocardial infarction for use in clinical laboratory or point of care settings",
    "fda_folder": "Clinical Chemistry"
}